- Home
- PLMR vs CORT Comparison
PLMR vs CORT Comparison
Compare PLMR & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PLMR | CORT |
|---|---|---|
| Founded | 2013 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.7B |
| IPO Year | 2019 | 2001 |
Fundamental Metrics
Financial Performance| Metric | PLMR | CORT |
|---|---|---|
| Price | $107.98 | $73.04 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $153.60 | $96.50 |
| AVG Volume (30 Days) | 220.1K | ★ 1.0M |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.04 | N/A |
| EPS | ★ 1.57 | N/A |
| Revenue | ★ $875,967,000.00 | $761,407,000.00 |
| Revenue This Year | $192.25 | $26.08 |
| Revenue Next Year | $19.34 | $26.98 |
| P/E Ratio | $69.11 | ★ N/A |
| Revenue Growth | ★ 58.16 | 12.79 |
| 52 Week Low | $100.81 | $28.66 |
| 52 Week High | $165.10 | $91.00 |
Technical Indicators
Market Signals| Indicator | PLMR | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 44.65 | 80.07 |
| Support Level | N/A | $68.20 |
| Resistance Level | $136.20 | $79.89 |
| Average True Range (ATR) | 4.43 | 2.57 |
| MACD | -0.24 | 0.87 |
| Stochastic Oscillator | 45.65 | 87.98 |
Price Performance
Historical ComparisonAbout PLMR Palomar Holdings Inc.
Palomar Holdings Inc that provides property and casualty insurance products to individuals and businesses. It provides insurance products serving five categories: Earthquake, Inland Marine and Other Property, Casualty, Fronting, and Crop. Company distribute products through multiple channels, including retail agents, program administrators, wholesale brokers, and partnerships with other insurance companies. The company's Earthquake product generate high premium.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.